Summary of Key Information:
Reporting Period: Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting - Financial Results under SEBI LODR Regulations 30 & 33
Audit Opinion:
Clean, unqualified audit opinion issued by Raman S. Shah & Co., Chartered Accountants for both standalone and consolidated financial results.
Key Financial Highlights [₹ lakhs]:
Standalone Results:
Revenue from Operations: 7,342.11 (Q1 FY27) vs 5,100.73 (Q1 FY26) - 44% YoY growth
Total Income: 7,427.37 (Q1 FY27) vs 5,167.85 (Q1 FY26)
Net Profit: 947.88 (Q1 FY27) vs 181.56 (Q1 FY26) - 422% YoY growth
EPS: ₹1.75 (Q1 FY27) vs ₹0.42 (Q1 FY26)
Other Equity: 54,312.50
Consolidated Results:
The consolidated results include subsidiary Valiant Advanced Sciences Private Limited.
Total Assets of consolidated entities: ₹45,491.02 lakhs
Total Income of consolidated entities: ₹11,528.51 lakhs
Total Net Profit after tax of consolidated entities: ₹2,110.30 lakhs for quarter ended June 30, 2026
Financial Performance Comparison:
Standalone Profit before tax: 1,272.80 (Q1 FY27) vs 244.57 (Q1 FY26)
Total Tax expense: 324.92 (Q1 FY27) vs 63.01 (Q1 FY26)
Cost of Materials consumed: 4,620.87 (Q1 FY27) vs 3,969.21 (Q1 FY26)
Employee benefit expenses: 122.09 (Q1 FY27) vs 119.01 (Q1 FY26)
Finance Cost: 7.65 (Q1 FY27) vs 7.33 (Q1 FY26)
Segment-wise Performance:
The company operates as a single segment company engaged in manufacturing of chemicals business. No separate reportable business segments.
Corporate Actions:
Not Specified
Other Significant Information:
No exceptional items reported
No change in accounting policy affecting comparability
No forward-looking guidance or management outlook provided
Company website: www.valiantlabs.in